Team:Paris Bettencourt/Notebook/Template.html

From 2013.igem.org

(Difference between revisions)
 
(24 intermediate revisions not shown)
Line 1: Line 1:
<html>
<html>
<head>
<head>
-
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:Paris_Bettencourt/css/Notebookstyle.css?action=raw&ctype=text/css&direction=cur" />
+
<style type="text/css">
 +
#tbnote {
 +
width: 75%;
 +
overflow: auto;
 +
overflow-x: auto;
 +
overflow-y: auto;
 +
}
 +
 
 +
#tbnote p {
 +
width: 65%;
 +
}
 +
</style>
 +
<!--<link rel="stylesheet" type="text/css" href="https://2013.igem.org/wiki/index.php?title=Team:Paris_Bettencourt/css/Notebookstyle.css&direction=cur&action=raw&ctype=text/css" />-->
</head>
</head>
<body>
<body>
Line 7: Line 19:
<h2> Drug Screening </h2>
<h2> Drug Screening </h2>
<h3> Day Number <sup>sup</sup> Month </h3>
<h3> Day Number <sup>sup</sup> Month </h3>
-
<a href="https://2013.igem.org/Team:Paris_Bettencourt/Project/Drug_Screen">
+
<a href="https://2013.igem.org/Team:Paris_Bettencourt/Project/Trojan_Horse">
 +
<img src="https://static.igem.org/mediawiki/2013/0/00/PB_Trojan_Horse_logo.png" height="30px" width="30px">
</a>
</a>
-
<b>
+
<p><b>sRNA design</b></p>
-
Add here your twit
+
<img src="https://static.igem.org/mediawiki/2013/4/4d/PB_TH_sRNA_Design.png"
-
</b>
+
    width="304" height="228"
-
<p>
+
    alt="sRNA Design"><br />
-
Add here your note
+
<br />
 +
Red sequences:<br />
 +
<br />
 +
pACYCDuet-1 (CmR) :  <span style="color:red">ATATCCAGTGATTTTTTTCTCCAT</span><br />
 +
pCOLADuet-1 (KanR) : <span style="color:red">CGTTTCCCGTTGAATATGGCTCAT</span><br />
 +
<br />
 +
We decided that targeting only two different antibiotic resistance will be enough for a proof of concept. We give up AmpR because otherwise they might be experimental issues with AmpR that is also on phagemid <em>litmus28i</em>.
</p>
</p>
</div>
</div>
</body>
</body>
</html>
</html>

Latest revision as of 02:09, 30 July 2013

Drug Screening

Day Number sup Month

sRNA design

sRNA Design

Red sequences:

pACYCDuet-1 (CmR) : ATATCCAGTGATTTTTTTCTCCAT
pCOLADuet-1 (KanR) : CGTTTCCCGTTGAATATGGCTCAT

We decided that targeting only two different antibiotic resistance will be enough for a proof of concept. We give up AmpR because otherwise they might be experimental issues with AmpR that is also on phagemid litmus28i.